Barrowclough, C, Haddock, C, Tarrier, N et al (2001) Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry; 158: 1706–13.
Brunette, MF, Mueser, KT (2006a) Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. Journal of Clinical Psychiatry; 67 (suppl 7): 10–7.
Brunette, MF, Drake, RE, Xie, H et al (2006b) Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin; 32: 637–43.
Buckley, PF, Thompson, P, Way, L et al (1994) Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. American Journal of Psychiatry; 151: 385–9.
Buckley, PF (1998) Substance abuse in schizophrenia. A review. Journal of Clinical Psychiatry; 3 (suppl 59): 26–30.
Burnam, MA, Morton, SC, McGlynn, EA et al (1995) An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. Journal of Addictive Diseases; 14: 111–34.
Cleary, M, Hunt, GE, Matheson, SL et al (2008) Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews; issue 4.
Denis, C, Lavie, E, Fatséas, M et al (2006) Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database of Systematic Reviews; issue 3.
Dixon, L, Haas, G, Weiden, PJ et al (1991) Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry; 148: 224–30.
Drake, RE, Xie, H, McHugo, GJ et al (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin; 26: 441–9.
Drake, RE, O'Neal, EL, Wallach, MA (2008) A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment; 34: 123–38.
Faber, MS, Fuhr, U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clinical Pharmacology and Therapeutics; 76: 178–84.
Green, AI (2006) Treatment of schizophrenia and co-morbid substance abuse: pharmacologic approaches. Journal of Clinical Psychiatry; 67 (suppl 7): 31–5.
Green, AI, Burgess, ES, Dawson, R et al (2003) Alcohol and cannabis use in schizophrenia. Effects of clozapine vs. Risperidone. Schizophrenia Research; 60: 81–5.
Green, AI, Tohen, MF, Hamer, RM et al (2004) First episode schizophrenia-related psychosis and substance use disorders. Acute response to olanzapine and haloperidol. Schizophrenia Research; 66: 125–35.
Green, AI, Noordsy, DL, Brunette, MF et al (2008) Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of Substance Abuse Treatment; 34: 61–71.
Haddock, G, Barrowclough, C, Tarrier, N et al (2003) Cognitive–behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry; 183: 418–26.
Harrison, I, Joyce, EM, Mutsatsa, SH et al (2007) Naturalistic follow-up of comorbid substance use in schizophrenia: the West London first-episode study. Psychological Medicine; 29: 1–10.
James, W, Preston, NJ, Koh, G et al (2004) A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychological Medicine; 34: 983–90.
Krabbendam, L, Arts, B, van Os, J et al (2005) Cognitive functioning in patients with schizophrenia and bipolar disorder. A quantitative review. Schizophrenia Research; 80: 137–49.
Martino, S, Carroll, K, Kostas, D et al (2002) Dual diagnosis motivational interviewing. A modification of Motivational Interviewing for substance-abusing patients with psychotic disorders. Journal of Substance Abuse Treatment; 23: 297–308.
McCambridge, J, Strang, J (2004) The efficacy of single-session motivational interviewing in reducing drug consumption and perceptions of drug-related risk and harm among young people: results from a multi-site cluster randomized trial. Addiction; 99: 39–52.
McEvoy, JP, Freudenreich, O, Levin, ED et al (1995) Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology; 119: 124–6.
Miller, WR, Rollnick, S (2002) Motivational Interviewing: Preparing People for Change. Guilford Press.
Miller, R, Caponi, JM, Sevy, S et al (2005) The Insight–Adherence–Abstinence triad: an integrated treatment focus for cannabis-using first-episode schizophrenia patients. Bulletin of the Menninger Clinic; 69: 220–36.
Potvin, S, Stip, E, Lipp, O et al (2006) Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Current Medical Research and Opinion; 22: 1277–85.
Prochaska, JO, DiClemente, CC (1992) Stages of change in modification of problem behaviours. Progress in Behavior Modification; 28: 183–218.
Sattar, SP, Bhatai, SC, Petty, F (2004) Potential benefits of quetiapine in the treatment of substance dependence disorders. Journal of Psychiatry and Neurosciences; 29: 452–7.
Schofield, D, Tennant, C, Nash, L et al (2006) Reasons for cannabis use in psychosis. Australian and New Zealand Journal of Psychiatry; 40: 570–4.
Stroup, S, Appelbaum, P, Swartz, MS et al (2005) Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research; 80: 1–8.
Weaver, T, Renton, A, Stimson, G et al (1999) Severe mental illness and substance misuse. Research is needed to underpin policy and services of patients with comorbidity. BMJ; 318: 137–8.
Ziedonis, DM, Trudeau, K (1997) Motivation to quit using substances among individuals with schizophrenia. Implications for a motivation-based treatment model. Schizophrenia Bulletin; 23: 229–38.
Zimmet, SV, Strous, RD, Burgess, ES et al (2000) Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder. A retrospective survey. Journal of Clinical Psychopharmacology; 20: 94–8.
Zullino, DF, Delessert, D, Eap, CB et al (2002) Tobacco and cannabis smoking cessation can lead to intoxication with clozapine and olanzapine. International Clinical Psychopharmacology; 17: 141–3.